Acrivon Therapeutics, Inc. Common Stock

10-Year Study

ACRV.US · Healthcare · US · Common Stock

Executive Summary: Acrivon Therapeutics, Inc. Common Stock has compounded at -19.5% annually over the last 10 years, with a maximum drawdown of 94.8% and an annualized volatility of 122.3%.

1Y CAGR
+98.6%
3Y CAGR
-45.8%
5Y CAGR
-29.9%
10Y CAGR
-19.5%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
94.8%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.02
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.03
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
66.8%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2024 · +22.4%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · -60.0%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
57%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-25.7-15.6-7.941.7————————-18.3%
20250.8-12.5-61.8-31.0-25.013.37.64.735.19.918.62.1-60.0%
2024-25.833.247.127.1-15.1-24.944.513.2-26.214.3-5.2-20.622.4%
202340.625.4-37.5-3.0-4.310.0-4.0-5.8-18.4-45.2-22.721.5-57.3%
20224.7-3.6-1.3-11.56.2-7.7-0.43.46.3-4.329.2-10.44.8%
20210.35.76.92.55.9-1.7-1.81.9-1.13.40.4-3.719.6%
20205.0-5.6-40.622.50.217.37.96.3-2.510.37.5-0.212.2%
2019————-6.0-6.6-4.3-1.57.31.60.7-0.0-9.2%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 122.3%. The dominant macroeconomic risk driver is VTI.US, accounting for 40.1% of variance. Idiosyncratic stock-specific factors contribute 21.8%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2019-04-0110000
2019-05-019396.219187159259
2019-06-018777.361312371031
2019-07-018395.935732900936
2019-08-018267.099275126218
2019-09-018873.924870570328
2019-10-019020.153671720456
2019-11-019083.052414633044
2019-12-019079.309297088375
2020-01-019531.343300611958
2020-02-018996.055305591792
2020-03-015346.403184153776
2020-04-016547.765898688398
2020-05-016562.39659677401
2020-06-017696.7598315206205
2020-07-018308.584702217726
2020-08-018828.661462011214
2020-09-018611.507292053602
2020-10-019496.134964373296
2020-11-0110208.475694352002
2020-12-0110183.175051123188
2021-01-0110212.405809301526
2021-02-0110790.87118815827
2021-03-0111540.69274826177
2021-04-0111824.749201616165
2021-05-0112527.833031813225
2021-06-0112314.682402339813
2021-07-0112092.896084802585
2021-08-0112318.838604547183
2021-09-0112181.581452900107
2021-10-0112593.31487447086
2021-11-0112647.136319629064
2021-12-0112175.028091870028
2022-01-0112752.51728088447
2022-02-0112295.456533562548
2022-03-0112137.526132094967
2022-04-0110740.297370245988
2022-05-0111403.501098530518
2022-06-0110522.73698276201
2022-07-0110484.982523666264
2022-08-0110839.222166862539
2022-09-0111516.797226775661
2022-10-0111021.60063017069
2022-11-0114235.25837125049
2022-12-0112761.881434770867
2023-01-0117946.395767646532
2023-02-0122510.540864109724
2023-03-0114058.010017989784
2023-04-0113637.045178995606
2023-05-0113049.910008819515
2023-06-0114357.116614117227
2023-07-0113781.05946601993
2023-08-0112983.441876346751
2023-09-0110590.589107327212
2023-10-015804.8835692881385
2023-11-014486.598941911633
2023-12-015450.386862766725
2024-01-014043.4780587598666
2024-02-015383.918730293961
2024-03-017920.785786337821
2024-04-0110069.922069623888
2024-05-018552.233044829089
2024-06-016425.252805700611
2024-07-019283.382502029504
2024-08-0110513.042952775655
2024-09-017754.61545515591
2024-10-018862.417663035325
2024-11-018397.14073572597
2024-12-016668.969291434081
2025-01-016724.359401828053
2025-02-015882.429723839696
2025-03-012248.8384819952134
2025-04-011550.9230910311817
2025-05-011163.1923182733865
2025-06-011318.2846273765044
2025-07-011417.9868260856522
2025-08-011484.454958558417
2025-09-012005.1219962617422
2025-10-012204.526393680037
2025-11-012614.413210595421
2025-12-012669.803320989392
2026-01-011982.965952104154
2026-02-011672.7813338979174
2026-03-011539.8450689523877
2026-04-012182.3703495224486
Annual Return Matrix
YearAnnual Return
20200.12158036673437356
20210.19560235690214722
20220.04820139538673551
2023-0.5729166666666666
20240.22357723577235755
2025-0.5996677740863787
2026-0.18257261410788383
Total Factor Risk
1.2229689791590874
VTI.US Exposure
0.4009472335857233
VEA.US Exposure
0.09141711902194795
VWO.US Exposure
-0.012008490756390652
QQQ.US Exposure
-0.028490375537955838
VTV.US Exposure
-0.01978436079317708
IJR.US Exposure
0.024627455376907945
QUAL.US Exposure
-0.01940706527996087
SHV.US Exposure
0.023285304389226956
TLT.US Exposure
0.0511047509443977
LQD.US Exposure
0.061882507807950134
HYG.US Exposure
0.004295814155873179
GLD.US Exposure
0.0006172024240322923
USO.US Exposure
0.0003400275383703462
VNQ.US Exposure
0.005753989129814438
BTC-USD.CC Exposure
-0.0016105042444557298
CPER.US Exposure
0.03743322359379869
VIX.INDX Exposure
-0.008747944491737701
UUP.US Exposure
0.050608961304295076
TIP.US Exposure
0.11959237272682087
Idiosyncratic Exposure
0.218142779104519
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
122.3%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Forward P/EForward P/E RatioA valuation metric that compares the current stock price to estimated future earnings per share.Click for full definition →No estimate availableN/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Squeeze RiskShort Squeeze RiskA situation where a sharp rise in the price of a stock forces short sellers to buy shares to cover their positions, further driving up the price.Click for full definition →Low
Market Cap$58.9M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators: distance from 50/200-Day SMA, 52-Week High proximity, Golden Cross trend signal, RSI momentum gauge, Fibonacci retracement levels, and Beta (market sensitivity).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+23.3%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+4.0%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
86.2% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.74
Market sensitivity coefficient
Trend SignalGolden Cross & Death CrossTechnical chart patterns that occur when a short-term moving average crosses over a long-term moving average.Click for full definition →
✦ Death Cross
Bearish — 50 SMA below 200 SMA
RSI (14-Day)Relative Strength Index (RSI)A momentum oscillator that measures the speed and change of price movements to identify overbought or oversold conditions.Click for full definition →
78
OversoldNeutralOverbought
Overbought
Fibonacci LevelsFibonacci RetracementTechnical levels based on mathematical ratios that indicate potential support and resistance areas.Click for full definition →
38.2% retracement-78.6%
50.0% retracement-74.3%
61.8% retracement-67.7%
% distance of current price from each 52-week Fibonacci support level.

Frequently Asked Questions & Methodology

Is Acrivon Therapeutics, Inc. Common Stock a high-risk investment?

Acrivon Therapeutics, Inc. Common Stock (ACRV.US) has an annualized volatility of 122.3% and experienced a maximum drawdown of 94.8% over the last 10 years. Its primary macro risk driver is VTI.US.

What is the 10-year return of ACRV.US?

Over the past 10 years, ACRV.US has generated a Compound Annual Growth Rate (CAGR) of -19.5%. It has had a positive return in 57% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Acrivon Therapeutics, Inc. Common Stock

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest